Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

BioMarin Pharmaceutical Inc. (BMRN) had Revenue of $776.13M for the most recently reported fiscal quarter, ending 2025-09-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-09-30

Income Statement Financials
Revenue	$776.13M
Net Income	$-30.74M
Cost of Goods Sold	$140.09M
Gross Profit	$636.05M
Operating Expenses	$822.83M
Operating Income	$-46.69M
Non-Operating Income/Expense	$20.37M
Pre-Tax Income	$-26.32M
Normalized Pre-Tax Income	$-26.32M
Income after Taxes	$-30.74M
Income from Continuous Operations	$-30.74M
Consolidated Net Income/Loss	$-30.74M
Normalized Income after Taxes	$-30.74M
EBIT	$-46.69M
EBITDA	$-29.18M
Weighted-Average Shares Outstanding (Basic)	192.03M
Weighted-Average Shares Outstanding (Diluted)	192.03M
Earnings per Share (EPS) (Basic)	$-0.16
Earnings per Share (EPS) (Diluted)	$-0.16
Balance Sheet Financials
Current Assets	$3.85B
Property, Plant, and Equipment	$1.04B
Long-Term Assets	$3.76B
Total Assets	$7.61B
Current Liabilities	$798.44M
Long-Term Debt	$596.66M
Long-Term Liabilities	$759.72M
Total Liabilities	$1.56B
Common Equity	$6.06B
Tangible Shareholders Equity	$5.63B
Shareholders Equity	$6.06B
Common Shares Outstanding	192.10M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$728.35M
Cash Flow from Investing Activities	$-371.79M
Cash Flow from Financial Activities	$-45.55M
Beginning Cash	$942.84M
End Cash	$1.25B
Increase/Decrease in Cash	$307.27M
Stock-Based Compensation	$134.50M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.83
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.09
Debt to Equity Ratio	0.10
Gross Margin	81.95%
Operating Margin	-6.02%
EBIT Margin	-6.02%
EBITDA Margin	--
Pre-Tax Profit Margin	-3.39%
Profit Margin	-3.96%
Free Cash Flow	$666.03M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.10
Inventory Turnover	0.10
Receiveable Turnover	0.98
Days Sales in Receivables	91.64
Return on Equity	-0.51%
Return on Tangible Equity	-0.55%
Return on Assets	-0.40%
Return on Investments	-0.46%
Book Value Per Share	$31.53
Free Cash Flow per Share	$3.47
Operating Cash Flow per Share	$3.79

Data from Zacks Investment Research, Inc.